Despite an urgent need for more effective and better tolerated psychopharmacological treatment options, the last years have seen very few additions to our pharmacological treatment options.
Esketamine, while approved by the FDA for treatment-resistant depression, remains under Priority Review through Health Canada. Several new treatment-options, including long acting formulations of buprenorphin, are now available for pharmacological treatment of opioid use disorder (Probuphine®, Sublocade®). Other medications were approved by the FDA but have not yet been submitted to Health Canada (brexanolone, cariprazine). Contrave® (naltrexone 8 mg / bupropion 90 mg) is a fixed-dose preparation of two previously approved agents for the pharmacological management of obesity. A safety-alert was recently issued on modafenil due to risk of congenital abnormalities.
This presentation will also review pharmacological treatment-options under investigation as well as the provincial iv ketamine program.